CoreBone

CoreBone’s coral-based biocactive bone graft material

CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to human and animal-derived (bovine, porcine) bone grafts.

CoreBones patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. The CoreBone graft offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.

CoreBone’s strictly controlled growing environment in its coral farm preserves the coral’s natural, bonelike properties.

• Similar qualities to human (allograft) bone, but derived from coral
• Better remodeling than bovine products (no heat treatment required); see more in Market
• Attractiveness to growing religious and vegetarian segments
• Competitive pricing
• Approved for dental and orthopedic implants

IP

• U.S. patent (2015)
• Israeli patent
• EU patent pending

• April 2019: Two successful surgeries using CoreBone material were conducted in the Orthopedic Oncology Department at Tel Aviv Sourasky Medical Center
• Sales in France, Poland, Israel
• March 2017 Product launch
• January 2017: Israel Ministry of Health approval
• Distribution agreements: Israel, France, Poland, Romania, and with a leading dental implant company
• October 2016: CE mark class III
• Ongoing studies with leading hospitals
• Highly positive feedback from KOLs: “Just like Bi-Oss” (the gold standard, global leader, bovine-derived)

CoreBone CEO Ohad Schwartz and a dentist from Singapore in the CoreBone booth, International Dental Show (IDS), Cologne, Germany, 3-6 March 2019.

September 2017 update

CoreBone continues to expand sales. “We presented our products at the largest dental show in Cologne, Germany,” says CEO Ohad Schwartz,” and received very positive feedback from visitors and distributors. Opinion leaders confirmed that the CoreBone material compares to the gold standard for dental bone graft. However, since we are not a bovine-derived product, our material is better replaced by bone (remodeling ) and appeals to segments (and countries) that are opposed to using human or animal derivatives.

“We are currently selling in France, Poland, Israel, and soon Romania, and have received distribution requests from other countries — and doctors — around the world. We signed a distribution agreement with a top dental implant company and give regular training sessions to customers and distributors. In this month alone, we are shipping 1,000 units.”

CoreBone earned CE mark and AMAR approval (from Israel’s Ministry of Health) to market its products in Israel and worldwide to the dental and orthopedic markets.

In the Media

• ynet: CoreBone is an Israeli success story
• Hamodia: Growing new bones
• Israel21c: Growing new bone from corals raised in the Israeli desert
• Israel21c: Top 12 disruptive technologies to watch in 2015
• CNN Marketplace Middle East: How a coral farm in the desert could help ‘grow bones’

CoreBone is now funding on Exit Valley.

Today, implants are used more and more in dental and orthopedics. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. *Furthermore, bovine-derived products hardly remodel due to the heat treatment that is essential to reduce viral risks. Synthetic materials, a fast-growing segment, lack strength.

Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion by 2022 (Allied Market Research). According to Transparency Market Research, the global dental membrane and bone graft substitutes market is expected to reach $922.6 million by 2024.